Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $244,315.16 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 27,116 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the transaction, the chief executive officer owned 1,535,082 shares in the company, valued at approximately $13,831,088.82. The trade was a 1.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Up 1.9%

Shares of NASDAQ:ARTV opened at $7.99 on Friday. The company’s 50 day moving average price is $8.40 and its two-hundred day moving average price is $5.70. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53. The firm has a market cap of $197.51 million, a PE ratio of -2.26 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, research analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the period. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth approximately $131,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $91,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth approximately $139,000.

Wall Street Analysts Forecast Growth

ARTV has been the topic of a number of analyst reports. Wedbush increased their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald increased their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC upped their price target on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artiva Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.